|
14.06.2016 20:50:00
|
Moody's: Acceleration of FDA Approvals is both blessing and curse for generic drugmakers
New York, June 14, 2016 -- An influx of new competition into the generic drug sector, driven in part by a more efficient FDA approval process, is pushing down prices and hurting drug companies' earnings, says Moody's Investors Service.
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.